Verified employee & interview reviews

PharmEasy Reviews

Mumbai, Maharashtra

4.0/ 5

1 review

PharmEasy is a prominent Indian digital healthcare platform operating as a consumer healthcare super app that integrates e-pharmacy, diagnostic testing, and teleconsultation services. Founded in 2015 by Dharmil Sheth and Dhaval Shah in Mumbai, Maharashtra, the company operates under its parent entity, API Holdings Private Limited. Under the leadership of CEO Siddharth Shah, PharmEasy has grown to become one of the largest online drugstores and healthtech ecosystems in India, focusing on making healthcare services easily accessible, affordable, and transparent. The core business model of PharmEasy focuses on connecting patients with local retail pharmacies and diagnostic centers through its centralized digital platform. The app provides on-demand, home-delivered access to a wide range of prescription medicines, over-the-counter pharmaceuticals, and wellness products. Beyond product delivery, the platform allows users to book comprehensive diagnostic medical tests and access online doctor consultations. By leveraging a vertically integrated supply chain and consolidating logistics, the platform streamlines pharmaceutical distribution across South Asia. PharmEasy’s growth has been significantly accelerated through major strategic mergers and acquisitions. In May 2021, the company acquired its rival e-pharmacy platform, Medlife, solidifying its dominant position in the domestic market. Later that year, in June 2021, the company completed a massive acquisition by purchasing a 66.1% controlling stake in Thyrocare Technologies, a nationwide diagnostics chain, for INR 4,546 crore. This acquisition transformed Thyrocare into the group's primary profit engine, enabling high-margin diagnostic packages, preventative health offerings, and at-home sample collection to complement the lower-margin medicine delivery segment. Additionally, PharmEasy acquired Aknamed, a healthcare supply chain company, to strengthen its enterprise capabilities. Operationally, PharmEasy enjoys a massive consumer footprint, boasting over 51 million registered users and servicing more than 19,000 pin codes across India. Despite its rapid scale and raising over $2.3 billion in total funding over time from prominent global investors like Goldman Sachs and ADQ, the company faced financial challenges, including a shelved IPO in 2022 and severe valuation corrections down to an estimated $710 million by 2024. In response, the management initiated a strategic turnaround strategy aimed at moving away from discount-heavy, growth-at-all-costs expansion toward strict unit economics and cost discipline. For the fiscal year 2025, PharmEasy reported an operating revenue of INR 5,872 crore, representing a modest annual increase, while successfully reducing its net losses by approximately 40% down to INR 1,517 crore. The company remains committed to structural cost controls, warehouse consolidation, and high-margin diagnostics expansion to achieve EBITDA break-even and sustainable net profitability by March 2027.